Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Hassan Website

Raffit Hassan, M.D.

Selected Publications

1)  Pastan I, Hassan R.
Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy.
Cancer Res. 74: 2907-2912, 2014.
[Journal]
2)  Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I.
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
Sci Transl Med. 5: 208ra147, 2013.
[Journal]
3)  Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D.
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.
Clin. Cancer Res. 16: 6132-8, 2010.
[Journal]
4)  Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I.
Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers.
Clin. Cancer Res. 13: 5144-9, 2007.
[Journal]
5)  Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M.
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.
Clin. Cancer Res. 12: 447-53, 2006.
[Journal]
6)  Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW, Hassan R, Armstrong TD, Jaffee EM.
A Listeria Vaccine and Depletion of T-regulatory Cells Activate Immunity Against Early-stage Pancreatic Intra-epithelial Neoplasms and Prolong Survival of Mice.
Gastroenterology. [Epub ahead of print], 2014.
[Journal]
7)  Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I.
A novel nomogram for peritoneal mesothelioma predicts survival.
Ann. Surg. Oncol. 20: 555-61, 2013.
[Journal]
8)  Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I.
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
Mol. Cancer Ther. 12: 48-57, 2013.
[Journal]
9)  Thomas A, Maltzman J, Hassan R.
Farletuzumab in lung cancer.
Lung Cancer. 80: 15-8, 2013.
[Journal]
10)  Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R.
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.
Am. J. Pathol. 182: 1065-77, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 7/7/2014.